BioLine RX Stock

BioLine RX Market capitalization

The The market capitalization of BioLine RX (BLRX.TA) as of Jun 12, 2026 is 11.78 T USD.In the previous year, The market capitalization was 11.78 T USD — a change of 0% (lower).

Market capitalization

11.78 TUSD

YoY

0%

Last updated:

In 2026, BioLine RX's market cap stood at 11.78 T USD, a 0% increase from the 11.78 T USD market cap in the previous year.

The BioLine RX Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market Capitalization (undefined USD)
Date
Market Capitalization (undefined USD)
Jan 1, 2005
0 base
Jan 1, 2006
0 base
Jan 1, 2007
0 base
Jan 1, 2008
0 base
Jan 1, 2009
0 base
Jan 1, 2010
0 base
Jan 1, 2011
0 base
Jan 1, 2012
0 base
Jan 1, 2013
0 base
Jan 1, 2014
0 base
Jan 1, 2015
0 base
Jan 1, 2016
0 base
Jan 1, 2017
0 base
Jan 1, 2018
0 base
Jan 1, 2019
0 base
YEARMarket Capitalization (undefined USD)
2024 -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
2006 -
2005 -
Access this data via the Eulerpool API
Get Free API Key

BioLine RX Stock analysis

What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring BioLine RX's Market Capitalization

BioLine RX's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of BioLine RX's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

BioLine RX's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in BioLine RX’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about BioLine RX stock

The market capitalization of BioLine RX amounted to 11.78 T USD 11.78 T

Access this data via the Eulerpool API
Get Free API Key

Valuation — BioLine RX

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — BioLine RX